Results 1 - 18 of 18 results
, Sato R, Adegawa S, Li X, Tanaka S, Endo H., Function and Role of ATP-Binding Cassette Transporters as Receptors for 3D- Cry Toxins. Toxins (Basel). January 1, 2019; 11 (2):
, Kaminski MM, Tosic J, Kresbach C, Engel H, Klockenbusch J, Müller AL, Pichler R, Grahammer F, Kretz O, Huber TB, Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors. Walz G, Arnold SJ, Lienkamp SS., Nat Cell Biol. December 1, 2016; 18 (12): 1269-1280.
, Tanaka S, Endo H, Adegawa S, Kikuta S, Sato R., Functional characterization of Bacillus thuringiensis Cry toxin receptors explains resistance in insects. FEBS J. January 1, 2016; 283 (24): 4474-4490.
, Choi MK, Kwon M, Ahn JH, Kim NJ, Bae MA, Song IS., Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator. Biopharm Drug Dispos. April 1, 2014; 35 (3): 183-94.
, Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T., Mol Pharm. May 6, 2013; 10 (5): 1783-94.
, Maciaszczyk-Dziubinska E, Wawrzycka D, Wysocki R., Arsenic and antimony transporters in eukaryotes. Int J Mol Sci. January 1, 2012; 13 (3): 3527-48.
, Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V, Surry D., In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. May 18, 2011; 43 (1-2): 41-9.
, Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD., Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. October 1, 2009; 15 (19): 6062-9.
, Ghibellini G, Leslie EM, Pollack GM, Brouwer KL., Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res. August 1, 2008; 25 (8): 1851-60.
, Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T., Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica. May 1, 2007; 37 (5): 474-86.
, Takekuma Y, Kakiuchi H, Yamazaki K, Miyauchi S, Kikukawa T, Kamo N, Ganapathy V, Sugawara M., Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. J Pharm Pharm Sci. January 1, 2007; 10 (1): 71-85.
, Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I., Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res. November 1, 2006; 23 (11): 2646-56.
, Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ., Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol. September 14, 2006; 72 (6): 729-38.
, Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T., OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. May 1, 2006; 34 (5): 862-9.
, Su Y, Zhang X, Sinko PJ., Human organic anion-transporting polypeptide OATP-A ( SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. January 12, 2004; 1 (1): 49-56.
, Diaz GJ., Basolateral and canalicular transport of xenobiotics in the hepatocyte: A review. Cytotechnology. November 1, 2000; 34 (3): 225-35.
, Madon J, Eckhardt U, Gerloff T, Stieger B, Meier PJ., Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett. April 7, 1997; 406 (1-2): 75-8.
, Erlinger S., Mechanisms of hepatic transport and bile secretion. Acta Gastroenterol Belg. April 1, 1996; 59 (2): 159-62.